NAVRATTAN MUNJAL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories promoter Navrattan Munjal, acting on behalf of all promoters and the promoter group, has filed the annual disclosure required under Regulation 31(4) of SEBI's Takeover Regulations for the financial year ended 31 March 2025. The filing confirms that the promoters and persons acting in concert with them have not created any new encumbrance (pledge, lien, or similar charge) on their shares during FY25, other than what has already been disclosed to the exchanges earlier. The list of 19 promoter and promoter-group entities (including Ind-Swift Limited, Essix Biosciences, and various Munjal/Mehta/Jain family members) is also attached for reference. This is a routine yearly compliance submission, not a transaction-triggered disclosure.
Neutral to mildly positive for shareholders – the filing reassures the market that promoters have not piled on additional pledges or encumbrances on their holdings in the past year, suggesting no fresh liquidity stress at the promoter level. No immediate impact on share price is expected as no buy, sell, or encumbrance event is being reported.